Regenicin, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported net loss was USD 0.639262 million compared to USD 0.670602 million a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 USD | +4,900.00% | 0.00% | +499,900.00% |
1st Jan change | Capi. | |
---|---|---|
+499,900.00% | 767K | |
-2.93% | 103B | |
+1.36% | 95.28B | |
+1.46% | 22.15B | |
-16.05% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.25% | 16.05B | |
+4.87% | 13.68B | |
+33.03% | 12.17B |
- Stock Market
- Equities
- RGIN Stock
- News Regenicin, Inc.
- Regenicin, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022